Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study
In PROpel, there were no differences in HRQoL or pain scores reported by patients with mCRPC receiving olaparib + abiraterone versus placebo + abiraterone, suggesting that patients can derive a clinical benefit from olaparib + abiraterone while maintaining similar HRQoL in comparison with current standard-of-care treatment. The PROpel trial is registered on ClinicalTrials.gov as NCT03732820.
Authors
- Jiří Navrátil (ORCID: https://orcid.org/0000-0001-5333-044X)
- David McGuinness (ORCID: https://orcid.org/0000-0003-2947-2047)
- Mustafa Özgüroğlu (ORCID: https://orcid.org/0000-0002-8417-8628)
- Denis Maillet (ORCID: https://orcid.org/0000-0002-5663-485X)
- Arnold Degboe
- Andrew J. Armstrong (ORCID: https://orcid.org/0000-0001-7012-1754)
- Gary L. Buchschacher (ORCID: https://orcid.org/0009-0000-5713-4155)
- Karina Vianna (ORCID: https://orcid.org/0000-0002-4864-7183)
- Fred Saad (ORCID: https://orcid.org/0000-0003-2986-5617)
- Christian Hosius
- Noel W. Clarke (ORCID: https://orcid.org/0000-0001-7776-8059)
- Craig Gedye (ORCID: https://orcid.org/0000-0002-1629-4352)
- Aníbal Salazar (ORCID: https://orcid.org/0000-0001-9319-4219)
- Hiroji Uemura (ORCID: https://orcid.org/0000-0001-7943-1564)
- Mototsugu Oya (ORCID: https://orcid.org/0000-0002-2048-4263)
- Urban Emmenegger (ORCID: https://orcid.org/0000-0002-3178-1896)
- Ji Youl Lee
- Juan Antonio Virizuela
Institutions
- AstraZeneca (United Kingdom) (GB)
- Kaiser Permanente (US)
- Keio University (JP)
- Salford Royal NHS Foundation Trust (GB)
- Yokohama City University Medical Center (JP)
- Hospital Universitario Virgen Macarena (ES)
- Salford Royal Hospital (GB)
- Istanbul University-Cerrahpaşa (TR)
- Hôpital Lyon Sud (FR)
- MSD (Germany) (DE)
- Masaryk Memorial Cancer Institute (CZ)
- Duke Medical Center (US)
- Instituto de Oncologia do Paraná (BR)
- Centre for Cancer Biology (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- AstraZeneca (United States) (US)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Sunnybrook Hospital (CA)
- Sunnybrook Research Institute
- Catholic University of Korea (KR)
- Yokohama City University (JP)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.euo.2025.09.010
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca